



Technical Report No. 69

Bioburden and Biofilm Management in Pharmaceutical Manufacturing Operations



PDA Bioburden and Biofilm Management in Pharmaceutical Manufacturing Operations Technical Report Team

Authors and Contributors

Vince Anicetti, Coherus Biosciences (Team Co-leader)

Marc Mittelman, Ph.D., Exponent (Team Co-leader)

Catherine Adley, Ph.D., University of Limerick

Peter Amin, Ph.D., U.S. FDA

John Arigo, Ph.D., U.S. FDA

Hal Baseman, Valsource, LLC

John Paul Bevel, Teva Pharmaceutical

Lucia Clontz, Ph.D., Xellia Pharmaceuticals

Sven Deutschmann, Ph.D., Roche Diagnostics GmbH

Rebecca A. Devine, Ph.D., Consultant to the Biopharmaceutical Industry

Mark Fornalik, Industrial Biofouling

Patricia Hughes, Ph.D., U.S. FDA

Anastasia Lolas, Visionary Pharma Consulting LLC

Randa Melhem, Ph.D., U.S. FDA

Peter Noverini, Azbil North America — BioVigilant Division

Mark Pasmore, Ph.D., Baxter

T.C. Soli, Ph.D., Soli Pharma Solutions, Inc.

Paul Sturman, Ph.D., Center for Biofilm Engineering

Kalavati Suvarna, Ph.D., U.S. FDA

Tyler Tsang, Genentech

George Verghese, STERIS Corporation

Carmen M. Wagner, Ph.D., Strategic Compliance International, Inc.

DISCLAIMER: The content and views expressed in this technical report are the result of a consensus achieved by the authoring task force and are not necessarily views of the organizations they represent.

Bioburden and Biofilm Management in Pharmaceutical Manufacturing Operations

Technical Report No. 69

ISBN: 978-0-93-945976-6

© 2015 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1	4.2.6 Materials.....	22
1.1 Scope and Purpose	1	4.2.6.1 Raw Material Sources	23
2.0 GLOSSARY OF TERMS	3	4.2.6.2 Raw Material Handling	23
3.0 OVERVIEW OF BIOBURDEN AND BIOFILMS	6	4.2.6.3 Material Container Handling	23
3.1 Bioburden Generation	6	4.3 Cleaning and Sanitization Program.....	23
3.2 Chemistry of Biofilm Formation	7	4.3.1 Types of Residues	24
3.3 Growth and Survival	8	4.3.2 Cleaning Processes.....	24
3.4 Microbial By-Products	8	4.3.2.1 Water Flush or Rinse	24
3.4.1 Endotoxins and Other Cell-Wall		4.3.2.2 Sanitization	24
Components.....	8	5.0 BIOBURDEN AND BIOFILM DETECTION AND	
3.4.2 Exotoxins and Other By-Products	8	CHARACTERIZATION	26
3.5 Impact of Fluid Flow on Biofilms.....	9	5.1 Sampling Points and Frequency.....	26
3.6 Biofilm-Remediation Considerations	11	5.1.1 Upstream Production.....	26
4.0 DESIGN, CONTROL, AND PREVENTION		5.1.2 Downstream Processing.....	27
CONSIDERATIONS	13	5.1.3 Monitoring Strategy.....	27
4.1 Overview of Microbial-Control Strategy.....	13	5.1.4 Process Sampling	27
4.1.1 Quality System.....	14	5.1.5 Equipment Sampling	28
4.1.2 Risk Assessment	14	5.2 Sampling Strategy	28
4.1.2.1 Ingress of Microorganisms.....	14	5.3 Microbial Levels and Limits	28
4.1.2.2 Proliferation of Microorganisms.....	14	5.3.1 Environmental Contamination	
4.1.2.3 Persistence of Microorganisms	15	Recovery Rates.....	29
4.2 Design Considerations	15	5.4 Recovery and Analysis of Biofilms.....	30
4.2.1 Facility Design.....	15	5.4.1 Biofilm Sampling.....	30
4.2.1.1 Construction Materials	15	5.4.2 Biofilm Analyses	31
4.2.1.2 Cleaning Program	15	5.5 Microbial By-Product Detection	33
4.2.1.3 Environmental Controls.....	16	5.5.1 Endotoxins	33
4.2.1.4 Workflow	16	5.5.2 Other Microbial By-Products.....	34
4.2.1.5 Waste	17	5.6 Alternative Microbial-Detection Methods	34
4.2.2 Equipment Design.....	17	5.6.1 Rapid Microbial Methods (RMMs).....	34
4.2.2.1 Soft Part Management.....	17	5.7 Microbial Test Method Validation.....	36
4.2.2.2 Leak Control.....	18	5.7.1 Method Suitability	36
4.2.2.3 Automation.....	18	5.7.2 Alternative Method Validation.....	37
4.2.2.4 Cleaning.....	18	5.7.2.1 Microscopy.....	37
4.2.2.5 Equipment Hold Time and Storage	18	5.7.2.2 Spectroscopy.....	37
4.2.3 Water Systems and Gas		5.7.2.3 Chromatography	37
Utilities Designs	19	5.8 Approaches to Laboratory Investigations	37
4.2.3.1 Water Quality.....	19	5.8.1 Launching Investigations	37
4.2.3.2 Water System Sanitization	19	5.8.2 Investigation Outcomes	38
4.2.3.3 Hose and Valve Maintenance	20	6.0 INVESTIGATION AND REMEDIATION	39
4.2.3.4 Process Gases	20	6.1 Organizing the Investigation Effort	39
4.2.4 Manufacturing-Process Design.....	20	6.1.1 Formation of Investigation and	
4.2.4.1 Single-Use Technology	21	Remediation Teams.....	39
4.2.4.2 In-Process Limits	21	6.2 Investigation	40
4.2.4.3 In-Process Hold Times.....	21	6.2.1 Verification of Initial Deviation Results	40
4.2.5 Personnel	22	6.2.1.1 Retesting, Resampling, and Collection	
		of Additional Samples.....	40
		6.2.1.2 Review of the Sampling Procedure.....	40

6.2.1.3 Review of Laboratory Environmental and Test Controls	41	7.1.3 The Investigation	48
6.2.1.4 Microbial identification	41	7.1.4 Root and Probable Causes	49
6.2.2 Root Cause Determination of Contamination.....	41	7.1.5 CAPAs.....	49
6.2.2.1 Risk Assessment.....	41	7.1.6 Verification of Effectiveness.....	49
6.2.2.2 Investigation of the Contamination Source	42	7.1.7 Lessons Learned	49
6.2.2.3 Investigation Considerations.....	43	7.2 Scenario 2: Biofilm in WFI System	49
6.2.2.3.1 Species of Contaminant(s).....	43	7.2.1 System and Process Description	49
6.2.2.3.2 Association with Recent Changes to the System or Past Problems	43	7.2.2 The Event.....	50
6.2.2.3.3 Supplemental Nonroutine Sampling	43	7.2.3 The Investigation	50
6.3 Remediation.....	43	7.2.4 Root and Probable Causes	50
6.3.1 Issues to Consider in Biofilm Removal	43	7.2.5 CAPAs.....	50
6.3.2 Cleaning and Sanitization Methods and Parameters.....	44	7.2.6 Verification of Effectiveness.....	50
6.3.2.1 Cleaning Step(s) for Biofilm Removal ..	44	7.2.7 Lessons Learned	50
6.3.2.2 Achieving Microbial Kill after Cleaning	44	7.3 Scenario 3: Insufficient Hot Water Sanitization of a Cold WFI Loop	50
6.3.2.3 Rinsing of Cleaning Agents and Disinfectants.....	45	7.3.1 System and Process Description	50
6.3.3 Equipment Replacement or Design Improvement.....	45	7.3.2 The Event.....	51
6.3.4 Preventive Actions.....	45	7.3.3 The Investigation	51
6.3.4.1 Ineffective Routine Sanitization Parameters	45	7.3.4 CAPAs.....	52
6.3.4.2 Untreated Surfaces.....	45	7.3.5 Verification of Effectiveness.....	52
6.3.4.3 Revision of Cleaning and Sanitization Indicators or Frequency	46	7.3.6 Lessons Learned	52
6.3.4.4 Correction of Poor Equipment or Process Design.....	46	7.4 Scenario 4: Contaminated Purified-Water Loop Due to Open Point-of-Use Dead Leg	52
6.4 Monitoring CAPA Effectiveness	46	7.4.1 System and Process Description	52
6.5 Communication of Investigation Results and Actions.....	46	7.4.2 The Event.....	52
6.5.1 Reviews of Risk-Assessment Reports	46	7.4.3 The Investigation	53
6.5.2 Regulatory Submission Notification or Modifications.....	46	7.4.4 CAPAs.....	53
6.5.3 Notification of Customers and Suppliers about Changes.....	46	7.4.5 Verification of Effectiveness.....	53
		7.4.6 Lessons Learned	53
7.0 CONTAMINATION SCENARIOS	48	7.5 Scenario 5: Nonsterile Batch Contamination by an External Biofilm	54
7.1 Scenario 1: Biofilm in Biologics Purification Equipment.....	48	7.5.1 System and Process Description	54
7.1.1 System and Process Description	48	7.5.2 The Event.....	54
7.1.2 The Event.....	48	7.5.3 The Investigation	54
		7.5.4 CAPAs.....	55
		7.5.5 Verification of Effectiveness.....	55
		7.5.6 Lessons Learned	55
		8.0 APPENDIX I: BIOPROCESS UNIT OPERATIONS AND TYPICAL PROCESS CONTROLS AND DETECTION	56
		9.0 APPENDIX II: TYPICAL BACTERIAL RESPONSE LIMITS FOR BIOPROCESSING	58
		10.0 REFERENCES	59

FIGURES AND TABLES INDEX

Figure 3.1-1	Bacterial biofilm on 316 stainless steel.. 6	Table 5.4.2-1	Biofilm Analysis Methods 32
Figure 3.1-2	Biofilm Formation and Generation..... 7	Table 5.4.2-2	Biofilm Analysis Techniques Using Removable Coupons 32
Figure 3.5-1	Fluid-Flow Velocity Profiles for Laminar (a) and Turbulent (b) Flow Conditions within a Pipe 10	Table 5.5-1	Possible Effects of Biofilm on Product..... 33
Figure 3.5-2	Laminar Boundary Sublayer Thickness in a Two-Inch Pipe..... 10	Table 5.5-2	Possible Effects of Biofilm on Process Performance 33
Fig 4.0-1	Effective (Risk-Based, Science-Based, and Proactive) Microbial-Control Program 13	Table 5.6.1-1	Current RMM Technologies 35
Figure 5.1-1	Microbial Contamination Control in Bioprocessing 26	Figure 6.0-1	Flow Diagram of Investigation and CAPA Steps for Effective Remediation 39
Table 5.4.1-1	Biofilm Recovery/Analysis Methods .. 31	Figure 6.2.2.1-1	Fault-Tree Analysis to Determine the Root Cause of a Contamination..... 42

1.0 Introduction

In the pharmaceutical industry, microbial-control issues are frequently cited in U.S. FDA inspectional observations and have resulted in recalls and/or medical shortages (1). In a review of more than 600 microbiology-related U.S. recalls of sterile and nonsterile products from 2004 to 2011, the majority resulted from a "lack of sterility assurance," indicating a potential problem with the product or packaging or that the manufacturer was unable to document that the product was manufactured in a state of control (2). Within the manufacturing environment, poor procedures, practices, and controls during the manufacture of sterile drug products and poorly designed environmental monitoring programs are frequent inspectional observations. Persistent bioburden and biofilm contamination have been implicated in at least one major recall that resulted in a medical shortage of parenteral products (1).

Management of bioburden, primarily biofilms, in pharmaceutical production processes is a major focus of quality programs. Yet, despite the significant resources used in bioburden contamination control efforts, bioburden contamination of manufacturing processes can be a significant cause of compromised product quality and adverse regulatory findings. Reasons for the persistent challenge of bioburden control include production processes that support microbial growth, use of nonsterile source materials, and human interfaces. This challenge is further complicated by the ability of microorganisms to survive and often flourish even in harsh environments (e.g., exposure to chemical sanitizers and disinfectants, high shear, and pressure). The formation of complex, adherent bacterial colonies ("biofilms") in fluid handling systems is a common adaptive strategy for many microorganisms and presents a significant challenge for their detection and control. Microorganisms growing within biofilms, along with planktonic cells that are present in a bulk phase environment, comprise bioburden in fluid handling systems.

In the latter part of the 20th century, there was a fundamental shift in the understanding of microbial growth in various environments. The commonly held historical perception of bioburden was that it consisted of individual planktonic (free-floating) organisms. The planktonic model has been the basis for most current bioburden management strategies; nearly all of the commercially available bioburden detection systems are based on planktonic cell detection. However, evidence accumulated over the past three decades suggests that biofilms are actually the preferred mode of microbial growth (3-5), with sessile cells sometimes outnumbering planktonic organisms by several orders of magnitude in a given environment. Since the planktonic model does not provide for adequate detection and control of biofilms, there is a need for an increased focus on the development of effective strategies and techniques for the detection and control of biofilms in overall bioburden prevention and control activities.

Microbial and, in particular, biofilm control remains a major challenge for the medical device and pharmaceutical industries. Similarly, in hospitals and other healthcare institutions, a knowledge gap exists in the detection and control of biofilm-related infections (6).

1.1 Scope and Purpose

A comprehensive program of bioburden management includes strategies for preventing and controlling biofilms and is based on current scientific knowledge of microbial growth and adaptation. This technical report presents the current scientific understanding of the causes of, and control strategies for, bioburden in pharmaceutical production systems, with a special emphasis on biofilms in fluid-handling systems. The scope of the report encompasses pharmaceutical and biopharmaceutical manufacturing processes but does not include final aseptic and terminal sterilization fill-finish operations. It is important to educate engineers, scientists and managers about the science of bioburden and biofilms because of the broad and complex challenge of bioburden management.